On August 17, 2026, a 60-year-old Massachusetts pharmacist pleaded guilty to diverting controlled prescription drugs while working as the only pharmacist on duty at a North Country Healthcare pharmacy in Lancaster, New Hampshire, in August 2024. The case is a textbook example of how solo coverage, delayed counts, and reactive camera review let personal-use diversion continue — and what a pharmacy can do to close that gap.

What Happened

She was the sole pharmacist on duty from August 6 to 9, 2024. Over that window, more than a dozen different types of medication — including stimulants and benzodiazepines — turned up missing. Security camera footage showed her opening medication bottles and ingesting medication while at work, and concealing pills: placing a tablet in a book that went into her purse, and doing the same with tissues.

The pharmacy's compliance team had flagged suspicious behavior, and the company that owned and managed the pharmacy reported the possible misuse to the DEA and terminated her. She waived indictment and pleaded guilty to acquiring or obtaining possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge (21 U.S.C. § 843(a)(3)). Sentencing is scheduled for November 23, 2026; she faces up to four years in prison.

Why Solo Coverage Is a Diversion Risk

  • One person, no witness. A sole pharmacist controls the stock, the dispensing workflow, and the records. There is no peer to observe access or challenge discrepancies at the moment they happen.
  • Counts happen after the fact. The shortages were discovered after the window closed, not reconciled at shift end. For per-diem coverage, the shift-change count is the primary control — and it was missing.
  • Cameras only help if someone watches. The concealment was visible on footage, but the review was reactive. Proactive review of flagged shifts is what catches behavior in time.
  • Temporary staff are higher risk. Per-diem and locum pharmacists lack the same relationship with the site's culture and controls, and are a recognized diversion risk population.

Controls That Close the Gap

  • Shift-change counts for high-risk drugs. Count stimulants and benzodiazepines at the start and end of every shift, and reconcile any variance before the pharmacist leaves.
  • Two-person integrity. Have a technician or manager witness access to high-value stock and sign the count — even on solo shifts.
  • Proactive camera review. Review footage for per-diem shifts, shortage-prone areas, and behavioral flags rather than waiting for an incident.
  • Per-diem onboarding and monitoring. Require controlled-substance policy sign-off, and apply extra reconciliation scrutiny to temporary coverage.
  • Act on behavioral observations. A documented protocol turns a compliance team's suspicion into a timely, formal review.
  • Report promptly. Theft or significant loss must be reported to the DEA — and preserving footage and records is what makes enforcement possible.

Read the Full Case

Massachusetts Pharmacist Pleads Guilty to Diverting Controlled Substances from New Hampshire Pharmacy — the full case study with sources.